Four years after buying Five Prime for $1.9 billion, Amgen has promising phase 3 results with a drug for gastric cancer that was the focal point for the deal. The new data comes from the FORTITUDE ...

Following its acquisition by Supernus Pharmaceuticals, Sage Therapeutics has let go of all of its remaining workforce, which ...

The results are very encouraging news for Amgen and Repatha, which is in a head-to-head marketing battle with Sanofi and Regeneron’s Praluent to be the dominant PCSK9 inhibitor.